300357 我武生物
已收盘 03-23 15:00:00
资讯
新帖
简况
我武生物(300357.SZ)获得人脐带间充质干细胞II型注射液药物临床试验申请受理
智通财经 · 03-11
我武生物(300357.SZ)获得人脐带间充质干细胞II型注射液药物临床试验申请受理
我武生物最新公告：获得狗毛皮屑点刺液药物临床试验补充申请批准通知书
证券之星 · 02-27
我武生物最新公告：获得狗毛皮屑点刺液药物临床试验补充申请批准通知书
我武生物最新公告：取得屋尘螨膜剂I期临床试验总结报告
证券之星 · 01-16
我武生物最新公告：取得屋尘螨膜剂I期临床试验总结报告
股市必读：我武生物（300357）1月15日董秘有最新回复
证券之星 · 01-16
股市必读：我武生物（300357）1月15日董秘有最新回复
我武生物：公司研发人员可借助大语言模型检索研发信息
证券之星 · 01-15
我武生物：公司研发人员可借助大语言模型检索研发信息
我武生物涨6.14%，西南证券二个月前给出“买入”评级
证券之星 · 01-05
我武生物涨6.14%，西南证券二个月前给出“买入”评级
创新药概念大幅拉升，我武生物涨超6%
证券之星 · 01-05
创新药概念大幅拉升，我武生物涨超6%
我武生物最新公告：获得豚草花粉点刺液药物临床试验补充申请批准通知书
证券之星 · 2025-11-21
我武生物最新公告：获得豚草花粉点刺液药物临床试验补充申请批准通知书
我武生物(300357.SZ)：终止烟曲霉点刺液研发项目
智通财经 · 2025-11-14
我武生物(300357.SZ)：终止烟曲霉点刺液研发项目
股市必读：我武生物（300357）10月30日董秘有最新回复
证券之星 · 2025-10-31
股市必读：我武生物（300357）10月30日董秘有最新回复
我武生物：异体间充质干细胞治疗药物处在临床前研究阶段
证券之星 · 2025-10-30
我武生物：异体间充质干细胞治疗药物处在临床前研究阶段
脱敏龙头我武生物盈利质量跃升，三季报多项核心数据亮眼，研发驱动构筑成长新范式
证券之星 · 2025-10-24
脱敏龙头我武生物盈利质量跃升，三季报多项核心数据亮眼，研发驱动构筑成长新范式
我武生物(300357.SZ)发布前三季度业绩，归母净利润3.45亿元，增长26.67%
智通财经 · 2025-10-23
我武生物(300357.SZ)发布前三季度业绩，归母净利润3.45亿元，增长26.67%
消息面利好叠加基本面稳健，我武生物股价大涨超10%
证券之星 · 2025-10-20
消息面利好叠加基本面稳健，我武生物股价大涨超10%
股市必读：我武生物（300357）10月10日董秘有最新回复
证券之星 · 2025-10-13
股市必读：我武生物（300357）10月10日董秘有最新回复
我武生物：专注国内市场暂无出海计划
证券之星 · 2025-10-10
我武生物：专注国内市场暂无出海计划
股市必读：我武生物（300357）9月30日董秘有最新回复
证券之星 · 2025-10-09
股市必读：我武生物（300357）9月30日董秘有最新回复
我武生物(300357.SZ)取得烟曲霉点刺液I期临床试验总结报告
智通财经 · 2025-09-25
我武生物(300357.SZ)取得烟曲霉点刺液I期临床试验总结报告
我武生物(300357.SZ)：皮炎诊断贴剂02贴药物临床试验申请获得受理
智通财经 · 2025-03-04
我武生物(300357.SZ)：皮炎诊断贴剂02贴药物临床试验申请获得受理
我武生物最新公告：获得皮炎诊断贴剂02贴药物临床试验申请受理通知书
证券之星 · 2025-03-04
我武生物最新公告：获得皮炎诊断贴剂02贴药物临床试验申请受理通知书
加载更多
公司概况
公司名称：
浙江我武生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2014-01-21
主营业务：
浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂以及粉尘螨皮肤点刺诊断试剂盒等系列点刺液产品。
发行价格：
20.05
{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"我武生物","latestPrice":23.57,"timestamp":1774249392000,"preClose":25.01,"halted":0,"volume":10793464,"delay":0,"changeRate":-0.0576,"floatShares":484000000,"shares":524000000,"eps":0.7457,"marketStatus":"已收盘","change":-1.44,"latestTime":"03-23 15:00:00","open":24.55,"high":24.66,"low":23.28,"amount":258000000,"amplitude":0.0552,"askPrice":23.57,"askSize":25,"bidPrice":23.55,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.7457,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"adjPreClose":25.01,"symbolType":"stock","openAndCloseTimeList":[[1774229400000,1774236600000],[1774242000000,1774249200000]],"highLimit":27.51,"lowLimit":22.51,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"isCdr":false,"pbRate":4.97,"roa":"--","peRate":31.607885,"roe":"13.8%","epsLYR":0.607,"committee":-0.131429,"marketValue":12341000000,"turnoverRate":0.0223,"status":1,"floatMarketCap":11409000000},"requestUrl":"/m/hq/s/300357","defaultTab":"news","newsList":[{"id":"2618917438","title":"我武生物(300357.SZ)获得人脐带间充质干细胞II型注射液药物临床试验申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2618917438","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618917438?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:49","pubTimestamp":1773218999,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物 发布公告，日前，公司间接控股子公司浙江我武干细胞科技有限公司获得国家药品监督管理局发出的《受理通知书》，由浙江干细胞提交的“人脐带间充质干细胞II型注射液”药物临床试验申请已获得正式受理。截至本公告披露日，国内外尚未有治疗脓毒症和脓毒性休克的间充质干细胞药物获批上市。脓毒性休克为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较单纯脓毒症更高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2614833482","title":"我武生物最新公告：获得狗毛皮屑点刺液药物临床试验补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2614833482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614833482?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:06","pubTimestamp":1772183192,"startTime":"0","endTime":"0","summary":"我武生物(300357.SZ)公告称，公司提交的“狗毛皮屑点刺液”药物临床试验补充申请获得批准。该药物为治疗用生物制品，剂型为皮肤点刺试剂，用于辅助诊断与狗毛皮屑致敏相关的I型变态反应性疾病。此次批准增加两种规格，并同意按新规格进行III期临床试验。该产品有望与公司已上市产品互为补充，满足更多过敏性疾病患者的检测需求。截至本公告披露日，经查询国家药品监督管理局网站，尚未有其他企业取得该品种的药品批准文号。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700027587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"gpt_icon":0},{"id":"2603096192","title":"我武生物最新公告：取得屋尘螨膜剂I期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2603096192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603096192?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:35","pubTimestamp":1768556128,"startTime":"0","endTime":"0","summary":"我武生物(300357.SZ)公告称，日前，公司研发的“屋尘螨膜剂”完成了一项“在中国成人尘螨变应性鼻炎患者中舌下含服‘屋尘螨膜剂’的安全性和耐受性临床研究——随机、双盲、安慰剂对照、剂量递增的I期临床试验”，并取得了I期临床试验总结报告。研究者认为，在该研究中使用的各维持剂量（150BU—2700BU）均可用于II期临床研究，将通过延长给药周期和扩大样本量进一步探索各剂量的有效性和安全性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600028899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"gpt_icon":0},{"id":"2603987386","title":"股市必读：我武生物（300357）1月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603987386","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603987386?lang=zh_cn&edition=full","pubTime":"2026-01-16 01:38","pubTimestamp":1768498690,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，我武生物报收于30.89元，下跌0.58%，换手率1.16%，成交量5.61万手，成交额1.73亿元。当日关注点来自交易信息汇总：1月15日主力资金净流出2565.91万元，散户资金净流入2205.81万元。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600000713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"gpt_icon":0},{"id":"2603867782","title":"我武生物：公司研发人员可借助大语言模型检索研发信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2603867782","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603867782?lang=zh_cn&edition=full","pubTime":"2026-01-15 16:21","pubTimestamp":1768465268,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物(300357)01月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司也是积极拥抱AI前沿技术来协同研发的，请问在AI+研发、AI+医疗等方面有哪些最新进展？我武生物回复：投资者您好，公司是一家专业从事过敏性疾病诊断及治疗产品的研发、生产和销售的高科技生物制药企业。公司研发人员可以借助各类大语言模型检索相关研发信息和资料，公司药品的研发进展可以关注公司的定期报告与相关临时公告。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500023599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"gpt_icon":0},{"id":"2601510006","title":"我武生物涨6.14%，西南证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2601510006","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601510006?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:44","pubTimestamp":1767599089,"startTime":"0","endTime":"0","summary":"今日我武生物涨6.14%，收盘报30.09元。2025年10月27日，西南证券研究员杜向阳发布了对我武生物的研报《2025年三季报点评：核心产品稳健增长，在研管线持续拓展》，该研报对我武生物给出“买入”评级。研报中预计2025-2027年净利润分别为3.9亿元、4.7亿元、5.7亿元，对应动态PE分别为45倍、37倍、30倍，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的王凯旋、陈竹、韩世通。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","300357"],"gpt_icon":0},{"id":"2601705280","title":"创新药概念大幅拉升，我武生物涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601705280","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601705280?lang=zh_cn&edition=full","pubTime":"2026-01-05 13:49","pubTimestamp":1767592183,"startTime":"0","endTime":"0","summary":"1月5日，A股创新药概念大幅走高，相关概念股普遍上涨，其中我武生物盘中一度涨超6%。消息面上，国家药监局数据显示，2025年我国已批准上市的创新药达76个，大幅超过2024年全年48个，创历史新高。2025年前三季度，我武生物营收与净利润均实现稳健增长。其中，“粉尘螨滴剂”作为基本盘贡献7.94亿元收入，同比增长13.38%；而“黄花蒿花粉变应原舌下滴剂”与“皮肤点刺液”两大产品线得益于市场推广加码，收入增速均超90%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026010500014527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","159992","06978","BK1574","BK1161","BK0239"],"gpt_icon":0},{"id":"2585811111","title":"我武生物最新公告：获得豚草花粉点刺液药物临床试验补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2585811111","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585811111?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:10","pubTimestamp":1763719854,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司提交的“豚草花粉点刺液”药物临床试验补充申请获得批准。该药品注册申请人为我武生物，注册分类为治疗用生物制品，剂型为皮肤点刺试剂，适应症为用于皮肤点刺试验，辅助诊断与豚草花粉致敏相关的I型变态反应性疾病。公司将根据进展情况及时履行信息披露义务。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100028343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"gpt_icon":0},{"id":"2583457545","title":"我武生物(300357.SZ)：终止烟曲霉点刺液研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2583457545","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583457545?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:44","pubTimestamp":1763109882,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物(300357.SZ)发布公告，日前，公司管理层对烟曲霉点刺液研发项目进行了审慎评估，综合项目进展情况、继续开发的风险等多种因素，为合理配置公司研发资源，聚焦研发管线中的优势项目，公司决定终止烟曲霉点刺液研发项目，不再开展后续的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300357","BK0239","BK0028"],"gpt_icon":0},{"id":"2579107343","title":"股市必读：我武生物（300357）10月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2579107343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579107343?lang=zh_cn&edition=full","pubTime":"2025-10-31 07:57","pubTimestamp":1761868631,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，我武生物报收于33.7元，下跌2.66%，换手率2.14%，成交量10.35万手，成交额3.51亿元。董秘最新回复投资者： 请问贵司干细胞研究的进展如何了？日本已经大量应用于临床了。当日关注点来自交易信息汇总：10月30日主力资金净流出687.72万元，游资资金净流入777.34万元。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100011034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2579948161","title":"我武生物：异体间充质干细胞治疗药物处在临床前研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2579948161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579948161?lang=zh_cn&edition=full","pubTime":"2025-10-30 16:15","pubTimestamp":1761812136,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物10月30日在投资者关系平台上答复投资者关心的问题。请问贵司的异体间充质干细胞治疗药物能带到多大的市场预期？在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000029316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"gpt_icon":0},{"id":"2577591836","title":"脱敏龙头我武生物盈利质量跃升，三季报多项核心数据亮眼，研发驱动构筑成长新范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2577591836","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577591836?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:23","pubTimestamp":1761297826,"startTime":"0","endTime":"0","summary":"证券之星注意到，这份“利润增速高于营收”的优质成绩单，源于我武生物主导产品的稳定增长与新产品的快速放量，更得益于其“研发驱动”的鲜明战略。在我国脱敏治疗市场，我武生物具备领先地位。单季度业绩逐季增长，表明我武生物盈利能力显著提升。截至2025年三季度末，我武生物的经营活动产生的现金流量净额达2.87亿元，同比大幅增长79.11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025102400031338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"gpt_icon":0},{"id":"2577130622","title":"我武生物(300357.SZ)发布前三季度业绩，归母净利润3.45亿元，增长26.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577130622","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577130622?lang=zh_cn&edition=full","pubTime":"2025-10-23 19:37","pubTimestamp":1761219453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物(300357.SZ)发布2025年三季度报告，该公司前三季度营业收入为8.53亿元，同比增长16.86%。归属于上市公司股东的净利润为3.45亿元，同比增长26.67%。归属于上市公司股东的扣除非经常性损益的净利润为3.4亿元，同比增长28.92%。基本每股收益为0.6587元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"我武生物(300357.SZ)发布前三季度业绩，归母净利润3.45亿元，增长26.67%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300357"],"gpt_icon":0},{"id":"2576365768","title":"消息面利好叠加基本面稳健，我武生物股价大涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576365768","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576365768?lang=zh_cn&edition=full","pubTime":"2025-10-20 15:40","pubTimestamp":1760946020,"startTime":"0","endTime":"0","summary":"10月20日，创新药概念股集体大涨，其中我武生物股价股价涨幅达10.07%，成交额达7.37亿元。从业绩基本面看，我武生物维持稳健增长态势。2025年半年报显示，公司营业收入为4.84亿元，同比上升12.81%；归母净利润为1.77亿元，同比上升18.61%；扣非归母净利润为1.73亿元，同比上升21.97%。海通国际证券指出公司核心品种粉尘螨滴剂稳步增长，新产品黄花蒿粉滴剂快速放量，点刺液产品不断丰富，研发领域也有多项进展，维持增持评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025102000015079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"gpt_icon":0},{"id":"2575485414","title":"股市必读：我武生物（300357）10月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2575485414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575485414?lang=zh_cn&edition=full","pubTime":"2025-10-13 02:53","pubTimestamp":1760295189,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，我武生物报收于29.42元，上涨1.94%，换手率2.74%，成交量13.28万手，成交额3.95亿元。公司产品黄花蒿花粉变应原舌下滴剂与皮肤点刺液产品三季度的销售情况请关注公司后续披露的2025年第三季度报告。当日关注点来自交易信息汇总：10月10日主力资金净流入1280.18万元，游资资金净流入3492.09万元，散户资金净流出4772.26万元。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300000970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"gpt_icon":0},{"id":"2574128790","title":"我武生物：专注国内市场暂无出海计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2574128790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574128790?lang=zh_cn&edition=full","pubTime":"2025-10-10 16:01","pubTimestamp":1760083269,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物10月10日在投资者关系平台上答复投资者关心的问题。黄花蒿和皮肤点刺34季度销售展望如何，我武生物回复：投资者您好，在变应原制品领域，目前公司专注国内市场。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000023050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"gpt_icon":0},{"id":"2574976460","title":"股市必读：我武生物（300357）9月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2574976460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574976460?lang=zh_cn&edition=full","pubTime":"2025-10-09 01:57","pubTimestamp":1759946231,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘，我武生物报收于29.19元，上涨2.24%，换手率2.16%，成交量10.44万手，成交额3.05亿元。董秘最新回复投资者： 董秘你好！交易信息汇总资金流向9月30日主力资金净流入1849.2万元，占总成交额6.06%；游资资金净流入3459.83万元，占总成交额11.34%；散户资金净流出5309.03万元，占总成交额17.4%。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900000594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"gpt_icon":0},{"id":"2570064267","title":"我武生物(300357.SZ)取得烟曲霉点刺液I期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2570064267","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570064267?lang=zh_cn&edition=full","pubTime":"2025-09-25 16:31","pubTimestamp":1758789065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物 ，公司研发的“烟曲霉点刺液”完成了“一项在中国志愿者中探索烟曲霉点刺液安全性及有效性的临床研究——单中心、开放的I期临床研究”，并取得了I期临床试验总结报告。烟曲霉点刺液在设定的剂量范围内具有良好的安全性，发生的不良事件均为1级或2级，未发生严重不良反应或导致退出的不良事件。在受试者中出现一定比例的迟发反应，提示可能与烟曲霉属于真菌的特性有关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","300357","BK0239"],"gpt_icon":0},{"id":"2516416623","title":"我武生物(300357.SZ)：皮炎诊断贴剂02贴药物临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516416623","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516416623?lang=zh_cn&edition=full","pubTime":"2025-03-04 17:41","pubTimestamp":1741081267,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物(300357.SZ)公告，公司获得国家药品监督管理局发出的《受理通知书》，由公司提交的“皮炎诊断贴剂02贴”药物临床试验申请已获得正式受理。相关适应症为：用于斑贴试验，辅助诊断与卡松、对苯二胺、甲醛致敏相关的变应性接触性皮炎。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300357","BK0239","BK1583","03347","BK0028","BK1141","BK1576"],"gpt_icon":0},{"id":"2516237626","title":"我武生物最新公告：获得皮炎诊断贴剂02贴药物临床试验申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2516237626","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516237626?lang=zh_cn&edition=full","pubTime":"2025-03-04 17:40","pubTimestamp":1741081256,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司获得国家药品监督管理局发出的《受理通知书》，由公司提交的“皮炎诊断贴剂02贴”药物临床试验申请已获得正式受理。如获得临床试验批准，本品后续将进行I期、II期、III期临床试验、上市许可申请等主要环节后方可上市销售，其结果存在较大不确定性。脱敏治疗结束后可以长期保持疗效。脱敏治疗是对因治疗，是一线治疗方法，应该尽早开始应用，不再以抗过敏药物失败为前提。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030400030569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1583","BK1141","300357","03347","BK0028","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774262828447,"stockEarnings":[{"period":"1week","weight":-0.0079},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.138},{"period":"6month","weight":-0.1269},{"period":"1year","weight":0.1619},{"period":"ytd","weight":-0.1149}],"compareEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.0171},{"period":"6month","weight":0.0359},{"period":"1year","weight":0.1608},{"period":"ytd","weight":-0.003}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32427人(较上一季度减少6.22%)","perCapita":"14927股","listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","registeredCapital":"52358万元","survey":" 浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂以及粉尘螨皮肤点刺诊断试剂盒等系列点刺液产品。","listedPrice":20.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"我武生物,300357,我武生物股票,我武生物股票老虎,我武生物股票老虎国际,我武生物行情,我武生物股票行情,我武生物股价,我武生物股市,我武生物股票价格,我武生物股票交易,我武生物股票购买,我武生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}